Market Closed -
London S.E.
11:35:12 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
1,913
GBX
|
+3.18%
|
|
+6.34%
|
+6.93%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,396
|
7,935
|
6,948
|
4,134
|
5,034
|
5,287
|
-
|
-
|
Enterprise Value (EV)
1 |
6,638
|
8,540
|
7,368
|
5,147
|
6,010
|
6,142
|
5,897
|
5,690
|
P/E ratio
|
13.2
x
|
19
x
|
16.6
x
|
22.5
x
|
26.8
x
|
12.5
x
|
12.1
x
|
11.9
x
|
Yield
|
1.67%
|
1.45%
|
1.8%
|
2.98%
|
3.16%
|
3%
|
3.12%
|
3.43%
|
Capitalization / Revenue
|
2.9
x
|
3.39
x
|
2.72
x
|
1.64
x
|
1.75
x
|
1.78
x
|
1.72
x
|
1.64
x
|
EV / Revenue
|
3.01
x
|
3.65
x
|
2.89
x
|
2.04
x
|
2.09
x
|
2.07
x
|
1.92
x
|
1.76
x
|
EV / EBITDA
|
11.2
x
|
12.7
x
|
10.1
x
|
7.42
x
|
7.41
x
|
7.73
x
|
6.99
x
|
6.35
x
|
EV / FCF
|
18.8
x
|
29.2
x
|
14.9
x
|
16.9
x
|
14.9
x
|
14.2
x
|
12.1
x
|
13.1
x
|
FCF Yield
|
5.32%
|
3.42%
|
6.69%
|
5.93%
|
6.72%
|
7.03%
|
8.27%
|
7.62%
|
Price to Book
|
3.02
x
|
3.72
x
|
2.83
x
|
1.94
x
|
2.29
x
|
2.1
x
|
1.88
x
|
1.68
x
|
Nbr of stocks (in thousands)
|
242,278
|
230,458
|
231,442
|
220,230
|
221,080
|
221,885
|
-
|
-
|
Reference price
2 |
26.40
|
34.43
|
30.02
|
18.77
|
22.77
|
23.83
|
23.83
|
23.83
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,203
|
2,341
|
2,553
|
2,517
|
2,875
|
2,972
|
3,075
|
3,234
|
EBITDA
1 |
593
|
674
|
727
|
694
|
811
|
794.8
|
843.3
|
896.2
|
EBIT
1 |
508
|
566
|
632
|
596
|
707
|
676.3
|
714.2
|
760.5
|
Operating Margin
|
23.06%
|
24.18%
|
24.76%
|
23.68%
|
24.59%
|
22.76%
|
23.22%
|
23.52%
|
Earnings before Tax (EBT)
1 |
465
|
522
|
544
|
233
|
281
|
547.7
|
586.6
|
626.9
|
Net income
1 |
486
|
431
|
421
|
188
|
190
|
419.2
|
450.6
|
475.4
|
Net margin
|
22.06%
|
18.41%
|
16.49%
|
7.47%
|
6.61%
|
14.11%
|
14.65%
|
14.7%
|
EPS
2 |
2.000
|
1.811
|
1.807
|
0.8360
|
0.8500
|
1.902
|
1.968
|
1.998
|
Free Cash Flow
1 |
353
|
292
|
493
|
305
|
404
|
431.7
|
487.7
|
433.3
|
FCF margin
|
16.02%
|
12.47%
|
19.31%
|
12.12%
|
14.05%
|
14.53%
|
15.86%
|
13.4%
|
FCF Conversion (EBITDA)
|
59.53%
|
43.32%
|
67.81%
|
43.95%
|
49.82%
|
54.31%
|
57.84%
|
48.35%
|
FCF Conversion (Net income)
|
72.63%
|
67.75%
|
117.1%
|
162.23%
|
212.63%
|
102.98%
|
108.25%
|
91.16%
|
Dividend per Share
2 |
0.4400
|
0.5000
|
0.5400
|
0.5600
|
0.7200
|
0.7153
|
0.7438
|
0.8180
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
---|
Net sales
1 |
1,160
|
1,132
|
1,209
|
1,216
|
1,337
|
1,213
|
1,304
|
1,427
|
1,448
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
282
|
309
|
-
|
296
|
300
|
-
|
306
|
Operating Margin
|
-
|
-
|
23.33%
|
25.41%
|
-
|
24.4%
|
23.01%
|
-
|
21.13%
|
Earnings before Tax (EBT)
|
-
|
-
|
248
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
219
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
18.11%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
0.9400
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
8/7/20
|
2/25/21
|
8/6/21
|
2/24/22
|
8/4/22
|
2/23/23
|
8/3/23
|
2/22/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
242
|
605
|
420
|
1,013
|
976
|
855
|
610
|
403
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.4081
x
|
0.8976
x
|
0.5777
x
|
1.46
x
|
1.203
x
|
1.075
x
|
0.7231
x
|
0.4494
x
|
Free Cash Flow
1 |
353
|
292
|
493
|
305
|
404
|
432
|
488
|
433
|
ROE (net income / shareholders' equity)
|
19.1%
|
20.3%
|
18.4%
|
17.7%
|
22.7%
|
19.3%
|
18.9%
|
18.8%
|
ROA (Net income/ Total Assets)
|
9.8%
|
10.7%
|
9.9%
|
9.18%
|
10.8%
|
9.91%
|
10.2%
|
10.3%
|
Assets
1 |
4,958
|
4,032
|
4,254
|
2,047
|
1,767
|
4,231
|
4,420
|
4,594
|
Book Value Per Share
2 |
8.750
|
9.260
|
10.60
|
9.690
|
9.950
|
11.40
|
12.70
|
14.20
|
Cash Flow per Share
2 |
1.940
|
1.950
|
2.740
|
2.360
|
2.730
|
2.840
|
3.280
|
3.430
|
Capex
1 |
119
|
172
|
229
|
225
|
204
|
193
|
206
|
220
|
Capex / Sales
|
5.4%
|
7.35%
|
8.97%
|
8.94%
|
7.1%
|
6.51%
|
6.71%
|
6.81%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
23.83
USD Average target price
28.64
USD Spread / Average Target +20.20% Consensus |
1st Jan change
|
Capi.
|
---|
| +6.93% | 5.29B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|